The clinical trial to study a new drug, AP-2.

2025-524480-21-00 Protocol MOLEFY-AP-2-2025-PHA Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 24 Apr 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol MOLEFY-AP-2-2025-PHA

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 72
Countries 1
Sites 1

ALS and related disorders like frontotemporal dementia and Alexander disease.

Key facts

Sponsor
Molefy Pharma S.L.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
24 Apr 2026 → ongoing
Decision date (initial)
2026-03-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

ALS and related disorders like frontotemporal dementia and Alexander disease.

VersionLevelCodeTermSystem organ class
21.1 PT 10068968 Frontotemporal dementia 100000004852
22.1 PT 10083059 Alexander disease 100000004850
27.1 PT 10002026 Amyotrophic lateral sclerosis 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Molefy Pharma S.L.

Sponsor organisation
Molefy Pharma S.L.
Address
Camino Las Mantecas Sn
City
San Cristobal De La Laguna
Postcode
38320
Country
Spain

Scientific contact point

Organisation
Molefy Pharma S.L.
Contact name
Sergio Capitán Herraiz

Public contact point

Organisation
Molefy Pharma S.L.
Contact name
Sergio Capitán Herraiz

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 72 1
Rest of world 0

Investigational sites

Spain

1 site · Ongoing, recruiting
Hospital Universitario De La Princesa
Clinical pharmacology, Calle De Diego De Leon 62, 28006, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2026-04-24 2026-04-27

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-15 Spain Acceptable with conditions
2026-03-09
2026-03-10
2 SUBSTANTIAL MODIFICATION SM-1 2026-03-18 Spain Acceptable
2026-03-19
2026-03-19
3 NON SUBSTANTIAL MODIFICATION NSM-1 2026-04-16 Spain Acceptable
2026-03-19
2026-04-16
4 SUBSTANTIAL MODIFICATION SM-2 2026-04-21 Spain Acceptable 2026-04-24
5 NON SUBSTANTIAL MODIFICATION NSM-2 2026-04-24 Spain 2026-04-24